MCID: PNC015
MIFTS: 35

Pancreatic Acinar Cell Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Pancreatic Acinar Cell Adenocarcinoma

MalaCards integrated aliases for Pancreatic Acinar Cell Adenocarcinoma:

Name: Pancreatic Acinar Cell Adenocarcinoma 12 14
Acinar Cell Adenocarcinoma of the Pancreas 69
Pancreatic Acinar Cell Carcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:5742
NCIt 46 C7977
UMLS 69 C0279661

Summaries for Pancreatic Acinar Cell Adenocarcinoma

Disease Ontology : 12 A pancreatic adenocarcinoma that has material basis in cells with morphological resemblance to acinar cells and is associated with increased serum lipase.

MalaCards based summary : Pancreatic Acinar Cell Adenocarcinoma, also known as acinar cell adenocarcinoma of the pancreas, is related to acinar cell carcinoma and acinar cell carcinoma of pancreas, and has symptoms including pruritus, icterus and abdominal pain. An important gene associated with Pancreatic Acinar Cell Adenocarcinoma is BCL10 (B Cell CLL/Lymphoma 10). The drugs Gemcitabine and Pancrelipase have been mentioned in the context of this disorder. Affiliated tissues include pancreas, breast and lung, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Pancreatic Acinar Cell Adenocarcinoma

Diseases related to Pancreatic Acinar Cell Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 24)
# Related Disease Score Top Affiliating Genes
1 acinar cell carcinoma 30.7 AFP BCL10 CHGA
2 acinar cell carcinoma of pancreas 11.2
3 pancreatitis 10.8
4 alpha-fetoprotein deficiency 10.1
5 panniculitis 10.1
6 orofaciodigital syndrome viii 10.1 AFP BCL10
7 adenocarcinoma 10.0
8 rh isoimmunization 10.0 AFP BCL10
9 adult teratoma 9.9 AFP CHGA
10 sclerosing hepatic carcinoma 9.9 AFP CHGA
11 testicular germ cell tumor 9.9 AFP BCL10
12 liver sarcoma 9.9 AFP CHGA
13 pancreatoblastoma 9.9 AFP CHGA
14 hepatitis 9.9
15 islet cell tumor 9.9
16 conn's syndrome 9.9
17 neuroendocrine tumor 9.9
18 acute pancreatitis 9.9
19 peritonitis 9.9
20 pancreatic cystadenocarcinoma 9.9 AFP CHGA
21 endodermal sinus tumor 9.8 AFP CHGA
22 tubular adenocarcinoma 9.8 AFP CHGA
23 cell type cancer 9.7 AFP CHGA
24 gastric adenocarcinoma 9.5 AFP CHGA

Graphical network of the top 20 diseases related to Pancreatic Acinar Cell Adenocarcinoma:



Diseases related to Pancreatic Acinar Cell Adenocarcinoma

Symptoms & Phenotypes for Pancreatic Acinar Cell Adenocarcinoma

UMLS symptoms related to Pancreatic Acinar Cell Adenocarcinoma:


pruritus, icterus, abdominal pain

GenomeRNAi Phenotypes related to Pancreatic Acinar Cell Adenocarcinoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-117 9.28 AFP CELA1
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-119 9.28 CELA1
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 9.28 CELA1
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-48 9.28 AFP
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 9.28 AFP
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 9.28 CELA1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-75 9.28 AFP
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-89 9.28 AFP

Drugs & Therapeutics for Pancreatic Acinar Cell Adenocarcinoma

Drugs for Pancreatic Acinar Cell Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 83)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
2
Pancrelipase Approved, Investigational Phase 3,Phase 2,Phase 1 53608-75-6
3
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
4
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1 68538-85-2
5
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
6
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
7
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
8 pancreatin Phase 3,Phase 2,Phase 1
9 Micronutrients Phase 3,Phase 2,Phase 1
10 Trace Elements Phase 3,Phase 2,Phase 1
11 Vitamin B Complex Phase 3,Phase 2,Phase 1
12 Vitamins Phase 3,Phase 2,Phase 1
13 Antidotes Phase 3,Phase 2,Phase 1
14 Anti-Infective Agents Phase 3,Phase 2,Phase 1
15 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
16 Antimetabolites Phase 3,Phase 2,Phase 1
17 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
18 Protective Agents Phase 3,Phase 2,Phase 1
19 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
20 Calcium, Dietary Phase 3,Phase 2,Phase 1
21 Antiviral Agents Phase 3,Phase 2,Phase 1
22
Erlotinib Hydrochloride Phase 3,Phase 1 183319-69-9 176871
23 Folate Nutraceutical Phase 3,Phase 2,Phase 1
24 Vitamin B9 Nutraceutical Phase 3,Phase 2,Phase 1
25
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
26
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
27
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
28
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
29
Oxaliplatin Approved, Investigational Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
30
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
31
Irinotecan Approved, Investigational Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
32
Metformin Approved Phase 2,Early Phase 1 657-24-9 4091 14219
33
nivolumab Approved Phase 2 946414-94-4
34
Ifosfamide Approved Phase 2 3778-73-2 3690
35
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
36 Bryostatin 1 Investigational Phase 2 83314-01-6
37
Camptothecin Experimental Phase 2,Phase 1 7689-03-4
38 Adjuvants, Immunologic Phase 2
39 Albumin-Bound Paclitaxel Phase 2,Phase 1
40 Gastrointestinal Agents Phase 2,Phase 1
41 Angiogenesis Inhibitors Phase 2
42 Angiogenesis Modulating Agents Phase 2
43 Anti-Bacterial Agents Phase 2,Phase 1
44 Antimitotic Agents Phase 2,Phase 1
45 Antibiotics, Antitubercular Phase 2,Phase 1
46 Antineoplastic Agents, Phytogenic Phase 2,Phase 1
47 topoisomerase I inhibitors Phase 2,Phase 1
48 Topoisomerase Inhibitors Phase 2,Phase 1
49 Antibodies, Monoclonal Phase 2
50 Hypoglycemic Agents Phase 2,Early Phase 1

Interventional clinical trials:

(show all 27)

# Name Status NCT ID Phase Drugs
1 Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer Completed NCT00058201 Phase 3 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
2 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery Recruiting NCT01013649 Phase 3 Capecitabine;Chemotherapy;Erlotinib Hydrochloride;Fluorouracil;Gemcitabine Hydrochloride
3 Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer Completed NCT00416793 Phase 2 bortezomib;carboplatin
4 Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy Completed NCT01658943 Phase 2 Akt Inhibitor MK2206;Fluorouracil;Oxaliplatin;Selumetinib
5 Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer Completed NCT01280058 Phase 2 Carboplatin;Paclitaxel
6 Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine Completed NCT00397787 Phase 2 sunitinib malate
7 Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas Completed NCT00085371 Phase 2 triapine
8 Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer Completed NCT00031694 Phase 2 paclitaxel;bryostatin 1
9 Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery Completed NCT01234935 Phase 2 dasatinib;gemcitabine hydrochloride
10 Combination Chemotherapy Before and After Surgery in Treating Patients With Localized Pancreatic Cancer Recruiting NCT02047474 Phase 2 oxaliplatin;leucovorin calcium;irinotecan hydrochloride;fluorouracil
11 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
12 Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer Active, not recruiting NCT01666730 Phase 2 metformin hydrochloride;oxaliplatin;leucovorin calcium;fluorouracil
13 Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Pancreatic Cancer Suspended NCT02178436 Phase 1, Phase 2 gemcitabine hydrochloride;paclitaxel albumin-stabilized nanoparticle formulation;selinexor
14 Mitomycin C and Ifosfamide in Treating Patients With Metastatic Pancreatic Cancer Terminated NCT00967291 Phase 2 ifosfamide;mitomycin C
15 CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Completed NCT01839981 Phase 1 6,8-bis(benzylthio)octanoic acid
16 Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride Completed NCT00981162 Phase 1 sorafenib tosylate;everolimus
17 Ultrasound-Guided Photodynamic Therapy With Photofrin & Gemcitabine for Patients With Locally Advanced Pancreatic Cancer Active, not recruiting NCT01770132 Phase 1 porfimer sodium;gemcitabine hydrochloride
18 CPI-613 and Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer Active, not recruiting NCT01835041 Phase 1 6,8-bis(benzylthio)octanoic acid;oxaliplatin;leucovorin calcium;irinotecan hydrochloride;fluorouracil
19 Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery Active, not recruiting NCT00669734 Phase 1
20 GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery Active, not recruiting NCT00878163 Phase 1 Erlotinib Hydrochloride;Gemcitabine Hydrochloride;Vismodegib
21 Alisertib and Gemcitabine Hydrochloride in Treating Patients With Solid Tumors or Pancreatic Cancer Active, not recruiting NCT01924260 Phase 1 alisertib;gemcitabine
22 Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies Active, not recruiting NCT01643499 Phase 1 oxaliplatin;irinotecan hydrochloride;leucovorin calcium;fluorouracil
23 Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery Suspended NCT01537107 Phase 1 vismodegib;sirolimus
24 Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery Terminated NCT01739439 Phase 1 gemcitabine hydrochloride
25 Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung Withdrawn NCT01741597 Phase 1
26 Stereotactic Radiosurgery and Metformin in Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer Recruiting NCT02153450 Early Phase 1 metformin hydrochloride
27 Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer Active, not recruiting NCT01821612 oxaliplatin;irinotecan;leucovorin;5-fluorouracil;capecitabine;gemcitabine

Search NIH Clinical Center for Pancreatic Acinar Cell Adenocarcinoma

Genetic Tests for Pancreatic Acinar Cell Adenocarcinoma

Anatomical Context for Pancreatic Acinar Cell Adenocarcinoma

MalaCards organs/tissues related to Pancreatic Acinar Cell Adenocarcinoma:

38
Pancreas, Breast, Lung, Liver

Publications for Pancreatic Acinar Cell Adenocarcinoma

Articles related to Pancreatic Acinar Cell Adenocarcinoma:

(show top 50) (show all 71)
# Title Authors Year
1
Murine Pancreatic Acinar Cell Carcinoma Growth Kinetics Are Independent of Dietary Vitamin D Deficiency or Supplementation. ( 28702373 )
2017
2
Liver Metastases in Pancreatic Acinar Cell Carcinoma Treated with Selective Internal Radiation Therapy with Y-90 Resin Microspheres. ( 29158927 )
2017
3
Pancreatic acinar cell carcinoma with extensive tumor embolism at the trunk of portal vein and pancreatic intraductal infiltration. ( 28921102 )
2017
4
Pancreatic acinar cell carcinoma presenting with panniculitis, successfully treated with FOLFIRINOX: A case report. ( 28588779 )
2017
5
Bouveret syndrome and pancreatic acinar cell carcinoma. ( 28135730 )
2017
6
Successful chemotherapy with modified FOLFIRINOX for pancreatic acinar cell carcinoma. ( 29052123 )
2017
7
Pancreatic acinar cell carcinoma: A review on molecular profiling of patient tumors. ( 29259370 )
2017
8
Clinical outcomes of patients with resectable pancreatic acinar cell carcinoma. ( 28671770 )
2017
9
Metastatic pancreatic acinar cell carcinoma in a younger male with marked AFP production: A potential pitfall on fine needle aspiration biopsy. ( 27634114 )
2016
10
TP53 alterations in pancreatic acinar cell carcinoma: new insights into the molecular pathology of this rare cancer. ( 26586531 )
2016
11
Efficacy of Chemotherapy in Patients with Unresectable or Metastatic Pancreatic Acinar Cell Carcinoma: Potentially Improved Efficacy with Oxaliplatin-containing Regimen. ( 27857025 )
2016
12
Cytological findings and BCL10 expression in pancreatic acinar cell carcinoma: A Case Report. ( 27860444 )
2016
13
A comparison study of pancreatic acinar cell carcinoma with ductal adenocarcinoma using computed tomography in Chinese patients. ( 27660464 )
2016
14
Pancreatic panniculitis as a paraneoplastic phenomenon of a pancreatic acinar cell carcinoma. ( 27112929 )
2016
15
KRAS Mutations in Canine and Feline Pancreatic Acinar Cell Carcinoma. ( 27290644 )
2016
16
Novel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatin. ( 27165126 )
2016
17
Pancreatic Acinar Cell Carcinoma. ( 27403122 )
2016
18
Long-term survival following pancreatectomy and s-1 chemotherapy for pancreatic acinar cell carcinoma with peritoneal dissemination: a case report and literature review. ( 25569665 )
2015
19
Ring around the ROSE: pancreatic acinar cell carcinoma diagnosed on site by EUS-FNA. ( 25805480 )
2015
20
Prolonged Survival in a Patient with a Pancreatic Acinar Cell Carcinoma. ( 26600777 )
2015
21
Clinical features and CT/MRI findings of pancreatic acinar cell carcinoma. ( 26628966 )
2015
22
Pancreatic acinar cell carcinoma with bilateral ovarian metastases, panniculitis and polyarthritis treated with FOLFIRINOX chemotherapy regimen. A case report and review of the literature. ( 25959244 )
2015
23
Sudden disappearance of the blood flow in a case of pancreatic acinar cell carcinoma. ( 25400180 )
2014
24
Clinical and CT imaging features of pancreatic acinar cell carcinoma. ( 23358813 )
2013
25
BCL10 as a useful marker for pancreatic acinar cell carcinoma, especially using endoscopic ultrasound cytology specimens. ( 23530562 )
2013
26
The CT findings of pancreatic acinar cell carcinoma in five cases. ( 23465983 )
2013
27
"Chronic" metastatic pancreatic acinar cell carcinoma. ( 24075523 )
2013
28
Comparison of pancreatic acinar cell carcinoma and adenocarcinoma using multidetector-row computed tomography. ( 24039366 )
2013
29
Pancreatic acinar cell carcinoma. ( 21982066 )
2012
30
FOLFOX regimen in pancreatic acinar cell carcinoma: case report and review of the literature. ( 21961498 )
2012
31
The utility of a novel antibody in the pathological diagnosis of pancreatic acinar cell carcinoma. ( 22228907 )
2012
32
Multimodal treatment of hepatic metastasis in the form of a bile duct tumor thrombus from pancreatic acinar cell carcinoma: case report of successful resection after chemoradiation therapy. ( 22949891 )
2012
33
Endoscopic ultrasound image of alpha-fetoprotein-producing pancreatic acinar cell carcinoma. ( 21944950 )
2012
34
Intraductal polypoid growth variant of pancreatic acinar cell carcinoma metastasizing to the intrahepatic bile duct 6 years after surgery: a case report and literature review. ( 22487469 )
2012
35
Huge pancreatic acinar cell carcinoma with high levels of AFP and fucosylated AFP (AFP-L3). ( 22687839 )
2012
36
Spontaneous rupture of a pancreatic acinar cell carcinoma presenting as an acute abdomen. ( 22543229 )
2012
37
Image of the month: Cystic variant of pancreatic acinar cell carcinoma. ( 22582413 )
2012
38
Functional pancreatic acinar cell carcinoma extending into the main pancreatic duct and splenic vein. ( 20703831 )
2012
39
An effective personalized approach to a rare tumor: prolonged survival in metastatic pancreatic acinar cell carcinoma based on genetic analysis and cell line development. ( 21475719 )
2011
40
Expression of claudin-5 in canine pancreatic acinar cell carcinoma - An immunohistochemical study. ( 21354944 )
2011
41
Analysis of LKB1 mutations and other molecular alterations in pancreatic acinar cell carcinoma. ( 21572398 )
2011
42
PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma. ( 20890270 )
2011
43
A case of pancreatic acinar cell carcinoma metastatic to skin. ( 21234254 )
2010
44
Pancreatic acinar cell carcinomas with prominent ductal differentiation: Mixed acinar ductal carcinoma and mixed acinar endocrine ductal carcinoma. ( 20182344 )
2010
45
Pancreatic acinar cell carcinoma: a multi-institutional study. ( 19495891 )
2009
46
Four cases of pancreatic acinar cell carcinoma treated with gemcitabine or S-1 as a single agent. ( 19666905 )
2009
47
The monoclonal anti-BCL10 antibody (clone 331.1) is a sensitive and specific marker of pancreatic acinar cell carcinoma and pancreatic metaplasia. ( 19066953 )
2009
48
Clinical challenges and images in GI: image 3. Pancreatic acinar cell carcinoma with subcutaneous fat necrosis. ( 18789332 )
2008
49
Cushing's syndrome in a child with pancreatic acinar cell carcinoma. ( 17917000 )
2007
50
Alpha-fetoprotein-producing pancreatic acinar cell carcinoma. ( 17711801 )
2007

Variations for Pancreatic Acinar Cell Adenocarcinoma

Expression for Pancreatic Acinar Cell Adenocarcinoma

Search GEO for disease gene expression data for Pancreatic Acinar Cell Adenocarcinoma.

Pathways for Pancreatic Acinar Cell Adenocarcinoma

GO Terms for Pancreatic Acinar Cell Adenocarcinoma

Cellular components related to Pancreatic Acinar Cell Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 8.92 AFP CEL CELA1 CHGA

Sources for Pancreatic Acinar Cell Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....